|
|
Dr. Zorn's research focuses on increasing access to genetic counseling and testing so that we can be proactive about management of inherited cancer risk. Read more>
|
|
|
TRI Now Seeking Applicants for 2021 KL2 Awards
|
|
The UAMS Translational Research Institute (TRI) is pleased to invite full applications for the 2021 KL2 Mentored Research Career Development Scholar Awards. KL2 Scholar Awards are part of the TRI Career Development Scholars Program which provides support for early-career UAMS faculty with a professional degree (M.D., Ph.D., Pharm.D., D.N.P., Dr.PH., D.O., etc.) who are committed to an academic career in multidisciplinary clinical or translational research.
The two-year program of intensive training combines an innovative educational program with mentored clinical/translational science research. KL2 Scholars are funded by the Clinical and Translational Science Award (CTSA) Program and will receive:
• Salary support/stipend of up to $95,000 (including fringe) per year.
• Up to $25,000 of non-salary support per year, which can be used for research, tuition, travel expenses, educational materials and other costs related to the scholar’s research.
The 2021 KL2 opportunity includes a Cancer Research Institutional Scholar Award, funded by the UAMS Winthrop P. Rockefeller Cancer Institute.
An informational session will be held via Zoom on January 14 at 1 p.m. More information is available on the TRI calendar.
View the Request for Applications document.
Important Dates:
January 14, 2021, KL2 Scholar Awards Informational Session, 1 – 2 p.m.
February 1, 2021, by 4:00 p.m.: Letter of Intent (LOI) due (non-binding)
February 26, 2021, Required Pre-Reviews and Authorizations Due
March 12, 2021, by 4:00 p.m., Proof of regulatory submission
March 19, 2021, by noon, Full applications due
May 3, 2021: Awardees notified
July 1, 2021: KL2 start date and earliest possible project start date
|
|
|
Jeannette Y. Lee, Ph.D., on Committee
To Review COVID-19 Vaccines
|
|
Jeannette Y. Lee, Ph.D., Cancer Institute member and professor in the Department of Biostatistics, recently reviewed and voted on FDA approval of the Pfizer vaccine to prevent COVID-19.
Lee serves as a temporary voting member on the FDA Vaccine and Related Biological Products Advisory Committee, which is reviewing applications for Emergency Use Authorization (EUA) for vaccines to prevent COVID-19. The FDA considers the committee’s recommendations in making its final recommendations for an EUA.
As more information becomes available, vaccine manufacturers are expected to submit applications for Biological License Authorization, which would mean full licensure for these products.
Lee also will participate in the review of the Moderna vaccine on Dec 17.
|
|
As 2020 draws to a close, we look back on a year of research achievements at the Winthrop P. Rockefeller Cancer Institute:
The fourth annual Proteomics Facility Staff Symposium brought together 30 proteomics core directors and staff members to learn how best to operate and maintain these facilities at their institutions.
A team led by UAMS cancer researcher Valentina Todorova, Ph.D., published their study titled “Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model” in Translational Oncology.
Three Seeds of Science small grant awards of $50,000 each were presented March 5 to UAMS cancer researchers at “The Doctor is in” event hosted by the Envoys volunteer advocacy group.
Fen Xia, M.D., Ph.D., received a $1.86 million NCI grant for her project titled “The Novel Role of Sirtuin 2 in Regulation of Transcription-Associated DNA Damage Repair.”
A research team led by Justin Leung, Ph.D., published their study titled “Histone H2A variants alpha1-extension helix directs RNF168-mediated ubiquitination” in the open-access journal Nature Communications.
A four-year grant of $894,074 to Fred Prior, Ph.D., gave UAMS a key role in an international effort using artificial intelligence to teach computers at local research centers how to recognize cancer.
The Cancer Institute announced the addition of 12 new oncologists.
A national database for patient cancer images at UAMS became the storage site for COVID-19 clinical images from across the United States and around the globe, including chest x-rays and CT scans of the body.
Fenghuang “Frank” Zhan, M.D., Ph.D., received two grants totaling almost $3.14 million to study the molecular genetics and drug resistance of multiple myeloma.
Analiz Rodriguez, M.D., Ph.D., received a $25,000 grant to further her gene expression research using targeted software.
The Radiation Oncology Residency program received accreditation from the Accreditation Council for Graduate Medical Education.
A $780,000 NCI grant to Tom Kelly, Ph.D., and Richard Nicholas, M.D., will fund a hands-on summer cancer research experience for medical students at UAMS.
A $10.6 million NIH grant to Alan Tackett, Ph.D., established the IDeA National Resource for Quantitative Proteomics as the first NIH National Resource in Arkansas.
Donald J. Johann, M.D., played an integral role in the publication of research by the Blood Profiling Atlas in Cancer Consortium (BloodPAC) related to liquid biopsies.
Led by Marjan Boerma, Ph.D., UAMS researchers received a five-year $11.4 million COBRE grant to continue research into the side effects of cancer therapies.
“Be a Part of the Cure,” the Cancer Institute’s first-ever televised fundraising event, raised more than $400,000 for research and treatment programs.
Justin Leung, Ph.D., received a five-year, $1.9 million NIH grant to advance his research of DNA damage response in cancer and genetic disorders.
Jesus Delgado-Calle, Ph.D., was awarded a $1.7 NCI million grant to study bone health in myeloma patients.
The University of Arkansas Board of Trustees approved joint ventures between UAMS, Baptist Health and Arkansas Children’s to expand access to radiation therapy, as well as establish the state’s first proton therapy center.
More than 160 scientists gathered online Oct. 30 for the first-ever UAMS – UA Fayetteville Collaborative Cancer Research Retreat.
The Cancer Institute opened a new infusion center that includes Arkansas’ first Phase I cancer clinical trial unit.
|
|
|
Cancer-related Research Funding Opportunities
|
|
Know someone at UAMS who needs to be added to our email list? Send their name to Susan Van Dusen, communications manager.
|
|
|
|
|
